secwatch.observer — SEC 8-K summary
======================================

Issuer:     WINDTREE THERAPEUTICS INC /DE/ (WINT)
CIK:        0000946486
Form:       8-K
Filed at:   2024-11-27T23:59:59+00:00
Accession:  0001437749-24-036346
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Windtree reports Q3 net loss $3.8M; cash runway only through Jan 2025
---------------------------------------------------------------------

- Operating loss $4.7M flat vs Q3 2023; net loss $3.8M ($4.23/share) vs $4.4M ($15.47/share) a year ago.
- Cash $2.3M at Sep 30; subsequent ELOC sales raised $2.4M net; funds only through January 2025.
- Positive Phase 2b istaroxime data in early cardiogenic shock: primary SBP AUC endpoint met; safety favorable.
- July 2024 private placements raised ~$13.9M aggregate ($4.4M new cash, $9.5M debt conversion); $35M ELOC secured.
- Nasdaq non-compliance for late 10-Q resolved after filing on Nov 26; listing compliance restored Nov 27.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946486/000143774924036346/0001437749-24-036346-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946486/000143774924036346/wint20240909_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-036346

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer